Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 107

1.

Effect of HIV infection and antiretroviral therapy on immune cellular functions.

Korencak M, Byrne M, Richter E, Schultz BT, Juszczak P, Ake JA, Ganesan A, Okulicz JF, Robb ML, de Los Reyes B, Winning S, Fandrey J, Burgess TH, Esser S, Michael NL, Agan BK, Streeck H.

JCI Insight. 2019 Jun 20;4(12). pii: 126675. doi: 10.1172/jci.insight.126675. eCollection 2019 Jun 20.

2.

Posttraumatic Stress Disorder and Neurocognitive Impairment in a U.S. Military Cohort of Persons Living with HIV.

Deiss R, Campbell CJ, Watson CW, Moore RC, Crum-Cianflone NF, Wang X, Ganesan A, Okulicz LCJ, Letendre S, Maves RC, Moore DJ, Agan BK.

Psychiatry. 2019 Mar 29:1-12. doi: 10.1080/00332747.2019.1586503. [Epub ahead of print]

PMID:
30925113
3.

Relationship between depression and risk behaviors in a US Military population with HIV infection.

Carney B, White J, Xu X, Sunil T, Daniels C, Byrne M, Ganesan A, Deiss R, Macalino G, Agan BK, Okulicz JF.

AIDS Care. 2019 Sep;31(9):1152-1156. doi: 10.1080/09540121.2019.1595522. Epub 2019 Mar 27.

PMID:
30917666
4.

Persistent Low-Level Viremia while on Antiretroviral Therapy is an Independent Risk Factor for Virologic Failure.

Joya C, Won SH, Schofield C, Lalani T, Maves RC, Kronmann K, Deiss R, Okulicz J, Agan BK, Ganesan A.

Clin Infect Dis. 2019 Feb 16. pii: ciz129. doi: 10.1093/cid/ciz129. [Epub ahead of print]

PMID:
30785191
5.

Extragenital chlamydia infection among active-duty women in the United States Navy.

Deiss R, Byrne M, Echols SM, Cammarata SM, Potswald L, Gomez E, Curry JA, Garges E, Macalino G, Agan BK, Bavaro MF.

Mil Med Res. 2019 Jan 29;6(1):3. doi: 10.1186/s40779-019-0193-x.

6.

Association between quantitative varicella-zoster virus antibody levels and zoster reactivation in HIV-infected persons.

Pomerantz HS, Xu X, White J, Sunil TS, Deiss RG, Ganesan A, Agan BK, Okulicz JF.

AIDS Res Ther. 2018 Dec 11;15(1):25. doi: 10.1186/s12981-018-0212-0.

7.

Lower health-related quality of life predicts all-cause hospitalization among HIV-infected individuals.

Emuren L, Welles S, Polansky M, Evans AA, Macalino G, Agan BK; Infectious Disease Clinical Research Program HIV Working Group.

Health Qual Life Outcomes. 2018 May 30;16(1):107. doi: 10.1186/s12955-018-0931-x.

8.

Brief Report: Racial Comparison of D-Dimer Levels in US Male Military Personnel Before and After HIV Infection and Viral Suppression.

OʼBryan TA, Agan BK, Tracy RP, Freiberg MS, Okulicz JF, So-Armah K, Ganesan A, Rimland D, Lalani T, Deiss RG, Tramont EC.

J Acquir Immune Defic Syndr. 2018 Apr 15;77(5):502-506. doi: 10.1097/QAI.0000000000001626.

9.

Evaluation of T and B memory cell responses elicited by the pandemic H1N1 vaccine in HIV-infected and HIV-uninfected individuals.

Sun P, Crum-Cianflone NF, Defang G, Williams M, Ganesan A, Agan BK, Lalani T, Whitman T, Brandt C, Burgess TH.

Vaccine. 2017 Oct 27;35(45):6103-6111. doi: 10.1016/j.vaccine.2017.09.059. Epub 2017 Oct 4.

PMID:
28987439
10.

Review of the U.S. military's human immunodeficiency virus program: a legacy of progress and a future of promise.

Okulicz JF, Beckett CG, Blaylock JM, Hakre S, Agan BK, Michael NL, Peel SA, Scott PT, Cersovsky SB.

MSMR. 2017 Sep;24(9):2-7. No abstract available.

PMID:
28953410
11.

Health-related quality of life among military HIV patients on antiretroviral therapy.

Emuren L, Welles S, Evans AA, Polansky M, Okulicz JF, Macalino G, Agan BK; Infectious Disease Clinical Research Program HIV Working Group.

PLoS One. 2017 Jun 7;12(6):e0178953. doi: 10.1371/journal.pone.0178953. eCollection 2017.

12.

Lower Baseline Germinal Center Activity and Preserved Th1 Immunity Are Associated With Hepatitis B Vaccine Response in Treated HIV Infection.

Paris RM, Milagres LG, Moysi E, Okulicz JF, Agan BK, Ganesan A, Petrovas C, Koup RA.

Pathog Immun. 2017;2(1):66-88. doi: 10.20411/pai.v2i1.175. Epub 2017 Mar 14.

13.

Brief Report: Prevalence of Posttreatment Controller Phenotype Is Rare in HIV-Infected Persons After Stopping Antiretroviral Therapy.

Perkins MJ, Bradley WP, Lalani T, Agan BK, Whitman TJ, Ferguson TM, Okulicz JF, Ganesan A.

J Acquir Immune Defic Syndr. 2017 Jul 1;75(3):364-369. doi: 10.1097/QAI.0000000000001393.

14.

The Association between Sexually Transmitted Infections, Length of Service and Other Demographic Factors in the U.S. Military.

Deiss R, Bower RJ, Co E, Mesner O, Sanchez JL, Masel J, Ganesan A, Macalino GE, Agan BK.

PLoS One. 2016 Dec 9;11(12):e0167892. doi: 10.1371/journal.pone.0167892. eCollection 2016.

15.

The per-protocol effect of immediate versus deferred antiretroviral therapy initiation.

Lodi S, Sharma S, Lundgren JD, Phillips AN, Cole SR, Logan R, Agan BK, Babiker A, Klinker H, Chu H, Law M, Neaton JD, Hernán MA; INSIGHT Strategic Timing of AntiRetroviral Treatment (START) study group.

AIDS. 2016 Nov 13;30(17):2659-2663.

16.

Vitamin D levels and influenza vaccine immunogenicity among HIV-infected and HIV-uninfected adults.

Crum-Cianflone NF, Won S, Lee R, Lalani T, Ganesan A, Burgess T, Agan BK.

Vaccine. 2016 Sep 22;34(41):5040-5046. doi: 10.1016/j.vaccine.2016.06.019. Epub 2016 Aug 28.

17.

Factors associated with 10 years of continuous viral load suppression on HAART.

Bello KJ, Mesner O, O'Bryan TA, Won SH, Lalani T, Ganesan A, Agan BK, Okulicz JF.

BMC Infect Dis. 2016 Jul 22;16:351. doi: 10.1186/s12879-016-1677-x.

18.

Generalized Confidence Intervals and Fiducial Intervals for Some Epidemiological Measures.

Bebu I, Luta G, Mathew T, Agan BK.

Int J Environ Res Public Health. 2016 Jun 18;13(6). pii: E605. doi: 10.3390/ijerph13060605.

19.

MRSA Infections in HIV-Infected People Are Associated with Decreased MRSA-Specific Th1 Immunity.

Utay NS, Roque A, Timmer JK, Morcock DR, DeLeage C, Somasunderam A, Weintrob AC, Agan BK, Estes JD, Crum-Cianflone NF, Douek DC.

PLoS Pathog. 2016 Apr 19;12(4):e1005580. doi: 10.1371/journal.ppat.1005580. eCollection 2016 Apr.

20.

D-Dimer Levels before HIV Seroconversion Remain Elevated Even after Viral Suppression and Are Associated with an Increased Risk of Non-AIDS Events.

Freiberg MS, Bebu I, Tracy R, So-Armah K, Okulicz J, Ganesan A, Armstrong A, O'Bryan T, Rimland D, Justice AC, Agan BK; Infectious Disease Clinical Research Program HIV Working Group.

PLoS One. 2016 Apr 18;11(4):e0152588. doi: 10.1371/journal.pone.0152588. eCollection 2016.

21.

The epidemiology of herpes simplex virus type 2 infections in a large cohort of HIV-infected patients, 2006-2014.

Koren M, Wang X, Blaylock JM, Okulicz JF, Whitman TJ, Deiss RG, Ferguson TM, O'Bryan TA, Sanchez JL, Lalani T, Agan BK, Macalino GE, Ganesan A.

MSMR. 2016 Mar;23(3):11-5. No abstract available.

PMID:
27030927
22.

Factors associated with HIV viral load "blips" and the relationship between self-reported adherence and efavirenz blood levels on blip occurrence: a case-control study.

Farmer A, Wang X, Ganesan A, Deiss RG, Agan BK, O'Bryan TA, Akers K, Okulicz JF.

AIDS Res Ther. 2016 Mar 22;13:16. doi: 10.1186/s12981-016-0100-4. eCollection 2016.

23.

Hospitalizations among HIV controllers and persons with medically controlled HIV in the U.S. Military HIV Natural History Study.

Crowell TA, Ganesan A, Berry SA, Deiss RG, Agan BK, Okulicz JF; Infectious Disease Clinical Research Program (IDCRP) HIV Working Group.

J Int AIDS Soc. 2016 Mar 7;19(1):20524. doi: 10.7448/IAS.19.1.20524. eCollection 2016.

24.

Characterizing the Association Between Alcohol and HIV Virologic Failure in a Military Cohort on Antiretroviral Therapy.

Deiss RG, Mesner O, Agan BK, Ganesan A, Okulicz JF, Bavaro M, Lalani T, O'Bryan TA, Bebu I, Macalino GE.

Alcohol Clin Exp Res. 2016 Mar;40(3):529-35. doi: 10.1111/acer.12975. Epub 2016 Feb 25.

25.

Toxoplasma gondii seroprevalence: 30-year trend in an HIV-infected US military cohort.

O'Bryan TA, Okulicz JF, Bradley WP, Ganesan A, Merritt SE, Agan BK.

Diagn Microbiol Infect Dis. 2016 Jan;84(1):34-35. doi: 10.1016/j.diagmicrobio.2015.09.008. Epub 2015 Sep 11.

PMID:
26499204
26.

Impact of the highly active antiretroviral therapy era on the epidemiology of primary HIV-associated thrombocytopenia.

O'Bryan TA, Okulicz JF, Bradley WP, Ganesan A, Wang X, Agan BK.

BMC Res Notes. 2015 Oct 23;8:595. doi: 10.1186/s13104-015-1548-3.

27.

Specific Behaviors Predict Staphylococcus aureus Colonization and Skin and Soft Tissue Infections Among Human Immunodeficiency Virus-Infected Persons.

Crum-Cianflone NF, Wang X, Weintrob A, Lalani T, Bavaro M, Okulicz JF, Mende K, Ellis M, Agan BK.

Open Forum Infect Dis. 2015 Mar 6;2(2):ofv034. doi: 10.1093/ofid/ofv034. eCollection 2015 Apr.

28.

Association between hepatitis B vaccine antibody response and CD4 reconstitution after initiation of combination antiretroviral therapy in HIV-infected persons.

Allen K, Mesner O, Ganesan A, O'Bryan TA, Deiss RG, Agan BK, Okulicz JF.

BMC Infect Dis. 2015 May 1;15:203. doi: 10.1186/s12879-015-0937-5.

29.

Seroprevalence and seroincidence of herpes simplex virus (2006-2010), syphilis (2006-2010), and vaccine-preventable human papillomavirus subtypes (2000-2010) among US military personnel.

Masel J, Deiss RG, Wang X, Sanchez JL, Ganesan A, Macalino GE, Gaydos JC, Kortepeter MG, Agan BK.

Sex Transm Dis. 2015 May;42(5):253-8. doi: 10.1097/OLQ.0000000000000277.

30.

HIV viraemia during hepatitis B vaccination shortens the duration of protective antibody levels.

O'Bryan TA, Rini EA, Okulicz J, Messner O, Ganesan A, Lalani T, Bavaro MF, O'Connell RJ, Agan BK, Landrum ML.

HIV Med. 2015 Mar;16(3):161-7. doi: 10.1111/hiv.12189. Epub 2015 Jan 14.

31.

Influence of the timing of antiretroviral therapy on the potential for normalization of immune status in human immunodeficiency virus 1-infected individuals.

Okulicz JF, Le TD, Agan BK, Camargo JF, Landrum ML, Wright E, Dolan MJ, Ganesan A, Ferguson TM, Smith DM, Richman DD, Little SJ, Clark RA, He W, Ahuja SK.

JAMA Intern Med. 2015 Jan;175(1):88-99. doi: 10.1001/jamainternmed.2014.4010.

32.

A single dose of benzathine penicillin G is as effective as multiple doses of benzathine penicillin G for the treatment of HIV-infected persons with early syphilis.

Ganesan A, Mesner O, Okulicz JF, O'Bryan T, Deiss RG, Lalani T, Whitman TJ, Weintrob AC, Macalino G, Agan BK; Infectious Disease Clinical Research Program HIV/STI Working Group.

Clin Infect Dis. 2015 Feb 15;60(4):653-60. doi: 10.1093/cid/ciu888. Epub 2014 Nov 10.

33.

Hepatitis B vaccine responsiveness and clinical outcomes in HIV controllers.

Okulicz JF, Mesner O, Ganesan A, O'Bryan TA, Deiss RG, Agan BK.

PLoS One. 2014 Aug 21;9(8):e105591. doi: 10.1371/journal.pone.0105591. eCollection 2014.

34.

HIV infection, antiretroviral therapy initiation and longitudinal changes in biomarkers of organ function.

So-Armah KA, Chang J, Alcorn C, Lo Re V, Baker JV, Tracy R, Butt AA, Agan BK, Rimland D, Gibert CL, Goetz MB, Oursler KK, Rodriguez-Barradas MC, Kuller LH, Brown ST, Stein JH, Skanderson M, Justice AC, Freiberg MS.

Curr HIV Res. 2014;12(1):50-9.

35.

HIV outcomes in Hepatitis B virus coinfected individuals on HAART.

Chun HM, Mesner O, Thio CL, Bebu I, Macalino G, Agan BK, Bradley WP, Malia J, Peel SA, Jagodzinski LL, Weintrob AC, Ganesan A, Bavaro M, Maguire JD, Landrum ML; Infectious Disease Clinical Research Program HIV Working Group.

J Acquir Immune Defic Syndr. 2014 Jun 1;66(2):197-205. doi: 10.1097/QAI.0000000000000142.

36.

Delayed-type hypersensitivity (DTH) test anergy does not impact CD4 reconstitution or normalization of DTH responses during antiretroviral therapy.

Minidis NM, Mesner O, Agan BK, Okulicz JF.

J Int AIDS Soc. 2014 Feb 4;17:18799. doi: 10.7448/IAS.17.1.18799. eCollection 2014.

37.

Combining epidemiologic and biostatistical tools to enhance variable selection in HIV cohort analyses.

Rentsch C, Bebu I, Guest JL, Rimland D, Agan BK, Marconi V.

PLoS One. 2014 Jan 29;9(1):e87352. doi: 10.1371/journal.pone.0087352. eCollection 2014.

38.

Race/ethnicity and HAART initiation in a military HIV infected cohort.

Johnson EN, Roediger MP, Landrum ML, Crum-Cianflone NF, Weintrob AC, Ganesan A, Okulicz JF, Macalino GE, Agan BK; Infectious Disease Clinical Research Program HIV Working Group.

AIDS Res Ther. 2014 Jan 24;11(1):10. doi: 10.1186/1742-6405-11-10.

39.

Expanded sexually transmitted infection surveillance efforts in the United States military: a time for action.

Sánchez JL, Agan BK, Tsai AY, Macalino GE, Wurapa E, Mbuchi M, Dueger E, Horton KC, Montano-Torres SM, Tilley DH, Saylors KE, Puplampu N, Duplessis CC, Harrison DJ, Putnam SD, Garges EC, Espinosa BJ, Dejli J, Meyers M, Yingst SL, Jerse AE, Maktabi HH, Burke RL, Jordan NN, Nowak G, Hsu K, Soge OO, Holmes KK, McClelland RS, MacDonald MR, Pavlin JA, Gaydos JC, Tramont EC.

Mil Med. 2013 Dec;178(12):1271-80. doi: 10.7205/MILMED-D-13-00137. Review. No abstract available.

PMID:
24306007
40.

The VACS index predicts mortality in a young, healthy HIV population starting highly active antiretroviral therapy.

Bebu I, Tate J, Rimland D, Mesner O, Macalino GE, Ganesan A, Okulicz JF, Bavaro M, Weintrob AC, Justice AC, Agan BK; Infectious Disease Clinical Research Program HIV Working Group.

J Acquir Immune Defic Syndr. 2014 Feb 1;65(2):226-30. doi: 10.1097/QAI.0000000000000045.

41.

Reply to Tsai et al.

Chun HM, Thio CL, Agan BK, Landrum ML; Infectious Disease Clinical Research Program HIV Working Group.

J Infect Dis. 2013 Oct 1;208(7):1186. doi: 10.1093/infdis/jit300. Epub 2013 Jul 9. No abstract available.

42.

CHALLENGES IN MANAGEMENT OF WARFARIN ANTI-COAGULATION IN ADVANCED HIV/AIDS PATIENTS WITH VENOUS THROMBOTIC EVENTS--A CASE SERIES FROM A RESEARCH CLINIC IN RURAL KERICHO, KENYA.

Tarus NK, Pau AK, Sereti I, Kirui FK, Sawe FK, Agan BK, Momanyi LM, Ngeno HC, Koskei GK, Shaffer DN.

East Afr Med J. 2013 Jul;90(7):207-13.

PMID:
26862618
43.

A comparison of HAART outcomes between the US military HIV Natural History Study (NHS) and HIV Atlanta Veterans Affairs Cohort Study (HAVACS).

Guest JL, Weintrob AC, Rimland D, Rentsch C, Bradley WP, Agan BK, Marconi VC; I D C R P H I V Working Group.

PLoS One. 2013 May 1;8(5):e62273. doi: 10.1371/journal.pone.0062273. Print 2013.

44.

Human papillomavirus seroprevalence among men entering military service and seroincidence after ten years of service.

Agan BK, Macalino GE, Nsouli-Maktabi H, Wang X, Gaydos JC, Ganesan A, Kortepeter MG, Sanchez JL.

MSMR. 2013 Feb;20(2):21-4.

45.

Low prevalence of neurocognitive impairment in early diagnosed and managed HIV-infected persons.

Crum-Cianflone NF, Moore DJ, Letendre S, Poehlman Roediger M, Eberly L, Weintrob A, Ganesan A, Johnson E, Del Rosario R, Agan BK, Hale BR.

Neurology. 2013 Jan 22;80(4):371-9. doi: 10.1212/WNL.0b013e31827f0776. Epub 2013 Jan 9.

46.

Identification of an abbreviated test battery for detection of HIV-associated neurocognitive impairment in an early-managed HIV-infected cohort.

Moore DJ, Roediger MJ, Eberly LE, Blackstone K, Hale B, Weintrob A, Ganesan A, Agan BK, Letendre SL, Crum-Cianflone NF.

PLoS One. 2012;7(11):e47310. doi: 10.1371/journal.pone.0047310. Epub 2012 Nov 8.

47.

Results of a 25-year longitudinal analysis of the serologic incidence of syphilis in a cohort of HIV-infected patients with unrestricted access to care.

Ganesan A, Fieberg A, Agan BK, Lalani T, Landrum ML, Wortmann G, Crum-Cianflone NF, Lifson AR, Macalino G; Infectious Disease Clinical Research Program HIV Working Group.

Sex Transm Dis. 2012 Jun;39(6):440-8. doi: 10.1097/OLQ.0b013e318249d90f.

48.

Hepatitis B vaccine antibody response and the risk of clinical AIDS or death.

Landrum ML, Hullsiek KH, O'Connell RJ, Chun HM, Ganesan A, Okulicz JF, Lalani T, Weintrob AC, Crum-Cianflone NF, Agan BK; Infectious Disease Clinical Research Program HIV Working Group.

PLoS One. 2012;7(3):e33488. doi: 10.1371/journal.pone.0033488. Epub 2012 Mar 22.

49.

Prevalence and factors associated with sleep disturbances among early-treated HIV-infected persons.

Crum-Cianflone NF, Roediger MP, Moore DJ, Hale B, Weintrob A, Ganesan A, Eberly LE, Johnson E, Agan BK, Letendre S.

Clin Infect Dis. 2012 May;54(10):1485-94. doi: 10.1093/cid/cis192. Epub 2012 Mar 19.

50.

Immunoglobulin G subclass levels and antibody responses to the 2009 influenza A (H1N1) monovalent vaccine among human immunodeficiency virus (HIV)-infected and HIV-uninfected adults.

Crum-Cianflone NF, Collins G, Defang G, Iverson E, Eberly LE, Duplessis C, Maguire J, Ganesan A, Agan BK, Lalani T, Whitman T, Brandt C, Faix D, Blair PJ, Burgess T.

Clin Exp Immunol. 2012 Apr;168(1):135-41. doi: 10.1111/j.1365-2249.2011.04550.x.

Supplemental Content

Support Center